EMEA-001064-PIP01-10-M03

Key facts

Invented name
  • Iblias
  • Kovaltry
Active substance
octocog alfa
Therapeutic area
Haematology-Hemostaseology
Decision number
P/0060/2018
PIP number
EMEA-001064-PIP01-10-M03
Pharmaceutical form(s)
Powder and solvent for solution for injection
Condition(s) / indication(s)
Treatment of hereditary factor VIII deficiency
Route(s) of administration
Intravenous use
Contact for public enquiries
Bayer AG

E-mail: clinical-trials-contact@bayer.com
Tel. +49 30300139003

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating